APVO
NASDAQAptevo Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks42+400%
2026-03-012026-08-23
Mix3090d
- Insider12(40%)
- SEC Filings10(33%)
- Market6(20%)
- Other2(7%)
Latest news
25 items- SECSEC Form PRE 14A filed by Aptevo Therapeutics Inc.PRE 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECSEC Form S-1 filed by Aptevo Therapeutics Inc.S-1 - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECAptevo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aptevo Therapeutics Inc.SCHEDULE 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)
- SECSEC Form 10-Q filed by Aptevo Therapeutics Inc.10-Q - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECAptevo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
- NEWSAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsMipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology PipelineNon-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor StrategyStrategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2026 and provide
- SECAptevo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
- NEWSAptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross ProceedsSEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company has issued new unregistered common stock purcha
- NEWSAptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross ProceedsSEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company will issue new unregistered common
- INSIDERDirector Harsanyi Zsolt converted options into 400 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERPresident and CEO Lamothe Jeffrey G. converted options into 961 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERSVP, CFO Taylor Daphne converted options into 638 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERSVP, GC, BD & Corp Affairs Kwon Soyoung converted options into 638 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERDirector Grant Grady Iii converted options into 400 shares, increasing direct ownership by 53% to 1,150 units (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERSVP, CMO Huebner Dirk converted options into 638 shares and covered exercise/tax liability with 156 shares (SEC Form 4) (tax liability)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERExecutive Chair White Marvin L converted options into 1,667 shares and covered exercise/tax liability with 406 shares (SEC Form 4) (withholding tax)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERDirector Abdun-Nabi Daniel converted options into 400 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERDirector Kunz Barbara Lopez converted options into 400 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- INSIDERDirector Niederhuber John converted options into 400 shares (SEC Form 4)4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)
- SECSEC Form DEF 14A filed by Aptevo Therapeutics Inc.DEF 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECAptevo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
- NEWSAptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting BackboneFiling supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo's oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation
- SECSEC Form S-8 filed by Aptevo Therapeutics Inc.S-8 - Aptevo Therapeutics Inc. (0001671584) (Filer)
- SECAptevo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
APVO FAQ
5 questionsWhat does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of...Where does APVO stock trade?
Aptevo Therapeutics Inc. (APVO) is listed on NASDAQ.What sector and industry is APVO in?
Aptevo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to APVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare APVO side-by-side with any of them on Quantisnow.How can I track APVO on Quantisnow?
Quantisnow aggregates Aptevo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APVO to receive live email and push alerts on every new disclosure.